Tevogen Bio (TVGN) : 8-month performance

Sector(s): Healthcare

Industry: Biotechnology

https://tevogen.com

 

 

 

Alset EHome (AEI) Prices Public Offering of Shares, Warrants

 

Alset EHome International Inc. said it has priced an underwritten public offering of 6.4 million common shares to be issued by the company at $2.12 a share.

 

 The holding company also is issuing pre-funded warrants to purchase 8.7 million shares at $2.11 per pre-funded warrant. The pre-funded warrants have an exercise price of one cent a share.

The proceeds from the offering, are expected to be $32 million.

Alset EHome granted the underwriters a 45-day option to purchase additional shares, representing up to 15% of the number of the shares and pre-funded warrants sold in the base offering, solely to cover over-allotments, if any.

Orphazyme (ORPH) : topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

• Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival
• Orphazyme remains focused on commercial readiness and potential U.S. approval of arimoclomol for Niemann-Pick disease type C (NPC) in June 
• Sept 29, 20: Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, raised $84 million by offering 7.6 million ADS equivalents at $11, below the as-converted last close of its shares on the Nasdaq Copenhagen (ORPHA). At pricing, the company raised -16% less in proceeds than anticipated.

Copenhagen – May 7, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety signals were reported in the trial. Topline data will be presented at the upcoming virtual European Network to Cure ALS (ENCALS) meeting, May 12-14, and complete data from the study will be published later this year.

“We are disheartened by these results, as we had hoped arimoclomol might represent a viable new approach against the formidable challenge of this devastating disease. We express our sincere thanks to the investigators, patients and families for their participation and collaboration in our program,” said Thomas Blaettler, MD, Chief Medical Officer, Orphazyme. “With over 18 months of evaluation, this trial represents one of the longest running clinical studies in this category. While unsuccessful, the data generated will contribute meaningfully to the scientific dialogue on this challenging disease. We will apply the invaluable insights from this and other studies to further our pipeline as we continue to pursue the full potential of the heat shock protein response.”

The randomized, placebo-controlled Phase 3 trial was conducted among 245 patients at 29 sites in 12 countries in North America and Europe. Participants were randomized (2:1 ratio) to receive either arimoclomol (248 mg three times daily)i or placebo for up to 76 weeks. The primary endpoint was to determine the efficacy of chronic treatment with arimoclomol compared to placebo in participants with ALS as assessed by the combined assessment of function and survival (CAFS). This endpoint was selected to illustrate the overall treatment effect based on survival and the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Secondary endpoints included survival, change in ALSFRS-R, and slow vital capacity (SVC).

About arimoclomol

Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 phase 1, four phase 2 and three pivotal phase 2/3 trials. Arimoclomol is in clinical development for NPC and Gaucher disease. Arimoclomol has received orphan drug designation (ODD) for NPC in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC. Arimoclomol is an investigational treatment and has not been approved by the FDA.

Zoom Video (ZM) reported earnings on Thur 5 Dec 19 (a/h)

** charts before earnings **

 

** charts after earnings **

Zoom Video beats on top and bottom lines; guides Q4 above consensus

Reports Q3 (Oct) earnings of $0.09 per share, after adjusting for stock-based compensation expense and related payroll taxes and undistributed earnings attributable to participating securities vs S&P Capital IQ Consensus of $0.03; revenues rose 84.9% year/year to $166.6 mln vs the $156.23 mln S&P Capital IQ Consensus. hird quarter of fiscal 2019. For the third quarter, GAAP operating margin was (1.0)% and non-GAAP operating margin. Approximately 74,100 customers with more than 10 employees, up approximately 67% from the same quarter last year. 546 customers contributing more than $100,000 in trailing 12 months revenue, up approximately 97% from the same quarter last year.

Co issues upside guidance for Q4, sees EPS of ~$0.07, excluding non-recurring items, vs. $0.04 S&P Capital IQ Consensus; sees Q4 revs of $175.0 million and $176.0 million vs. $166.65 mln S&P Capital IQ Consensus.

Dell (DELL) reported earnings on Thur 29 Aug 2019 (a/h)

** charts after earnings **

 

Dell beats by $0.66, reports revs in-line

Reports Q2 (Jul) adjusted earnings of $2.15 per share, $0.66 better than the S&P Capital IQ Consensus of $1.49; revenues rose 1.9% year/year to $23.37 bln vs the $23.32 bln S&P Capital IQ Consensus. 

"We are in the early stages of a technology-led investment cycle. IT spending remains healthy and our business drivers remain strong," said Jeff Clarke, vice chairman, Dell Technologies. "We are innovating and integrating across the Dell Technologies portfolio, from the edge to the core to the cloud, with a diverse business designed to succeed in any macro environment. For example, core Dell orders were up four percent in the quarter excluding China."

=Opera (OPRA), began trading on the Nasdaq on 27 July 2018

Opera (OPRA), the Norway-based maker of web browsers for PCs and mobile phones, went public on July 27 at $12 a share.

Long trade : LBRT +20% (9/18)

• 10 Sept.:  vol. 1.09M;  $17.80

Casa Systems (CASA) reported earnings on Tue 14 Aug 2018 (a/h)

** charts before earnings **

 

** charts after earnings **

 

Casa Systems beats by $0.01, misses on revs; guides FY18 EPS below consensus, revs below consensus, announces $75 mln stock repurchase program 

• Reports Q2 (Jun) earnings of $0.24 per share, $0.01 better thanthe Capital IQ Consensus of $0.23; revenues rose 3.2% year/year to $68.7 mln vs the $90.64 mln Capital IQ Consensus.
• Reports gross margin of 71.9%, compared to gross margin of 68.7% in 2Q17.
• Co issues downside guidance for FY18, sees EPS of $0.80-$0.88 vs. $1.14 Capital IQ Consensus Estimate; sees FY18 revs of $330-$350 mln vs. $390.57 mln Capital IQ Consensus Estimate.
• Commentary: "...While we are disappointed with the moderation in our top-line growth during the second quarter, we believe that this is related to the timing of several projects involving network transformation and capacity upgrades. Given the forward pipeline in all three of our end markets, I am as enthusiastic as ever about the outlook for the company. Based on our confidence in the future of the business and commitment to delivering value to our shareholders, we are announcing a stock repurchase program for up to $75 million of shares of common stock ..."

SendGrid (SEND) began trading on the NYSE on Wed 15 Nov 2017

• Update Oct 15, 18: SendGrid (SEND) to be acquired by Twilio (TWLO) for $2 billion
• ------
• The company had priced its stock at $16 a share on the day before its IPO, which would bring in about $131 million. 
• It opened at $18.55, or 16 percent higher, and hit a high of $19.21. The price hovered around $18 for most of the morning, closing at $18.00, up 12.5 percent on its first day.

SendGrid, which got an early start at the Techstars accelerator in Boulder, built its business on transactional emails and making sure its clients got their messages to their customers’ inboxes — from Uber ride receipts and Spotify password resets to  salary updates on Glassdoor.

In the Denver tech community, SendGrid is known for its work culture and promoting its four H’s: honest, hungry, humble and happy. Many in the community expressed their excitement on Twitter, such as Erik Mitisek, the state’s chief innovation officer.

Executives and guests of SendGrid, Inc. visit the New York Stock Exchange to celebrate their IPO. To mark the occasion Chief Executive Officer, Sameer Dholakia, alongside Tom Farley, President, NYSE, ring The Opening Bell.

CEO Sameer Dholakia and SendGrid’s three founders — Isaac Saldana, Tim Jenkins and Jose Lopez — rang the morning bell to open the NYSE.

SendGrid isn’t yet profitable, but it has seen revenues rise since it was founded in 2009. In its first nine months this year, sales hit $80.2 million, which is higher than all of 2016. Net losses grew 36 percent to $4.7 million in the first nine months of this year, from the same period last year. It has also grown from three founders to 408 employees in its eight years.

Heimes said the company is going after an $11 billion email market, of which SendGrid has less than 3 percent. The company has expanded into marketing messages and is targeting international customers — growth areas that may explain why the company’s stock price went beyond last week’s proposed targeted price range of $13.50 to $15.50.

=Laureate (LAUR) : 8-month performance

Virgin America (VA) : 8-month performance

daily Heikin Ashi

Alibaba (BABA) : 8-month performance

Globant (GLOB) : 8-month performance

Globant (GLOB) : 8-month performance

GoPro (GPRO) : 8-month performance

Tableau (DATA) reported earnings on 4 Feb 2015 a/h

Civeo (CVEO) : 8-month performance

JD.com (JD) : 8-month performance

Agile Therapeutics (AGRX) : 8-month performance

Cheetah Mobile (CMCM) : 8-month performance